<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082701</url>
  </required_header>
  <id_info>
    <org_study_id>STR-005-001</org_study_id>
    <nct_id>NCT05082701</nct_id>
  </id_info>
  <brief_title>Sentinel™ Trial: A Prospective Study Evaluating Combined Comprehensive Genomic and Transcriptomic Profiling With ctDNA Testing for Recurrence Detection and Treatment Monitoring of Patients With Solid Tumors</brief_title>
  <acronym>Sentinel</acronym>
  <official_title>Sentinel™ Trial: A Prospective Study Evaluating Combined Comprehensive Genomic and Transcriptomic Profiling With ctDNA Testing for Recurrence Detection and Treatment Monitoring of Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Strata Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Strata Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Sentinel Trial is a non-randomized, large-scale observational trial designed to: 1)&#xD;
      determine the accuracy of StrataMRD for predicting radiographic and/or biochemical&#xD;
      recurrence, and 2) compare the clinical benefit of biomarker guided adjuvant therapy versus&#xD;
      standard adjuvant therapy in ctDNA-positive participants. The study offers the opportunity to&#xD;
      monitor participants, define ctDNA kinetics across tumor and therapy types, and identify&#xD;
      participants with ctDNA evidence of minimal residual disease (MRD) that are at high risk of&#xD;
      recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants are those with confirmed diagnosis of a stage 1-3 solid tumor. Patients&#xD;
      who have leftover or surplus formalin fixed paraffin embedded tumor specimens, or a planned&#xD;
      resection within 28 days of screening, may be eligible to participate in Sentinel. Study&#xD;
      procedures will be limited to repeat blood draws to support ctDNA assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>7 Years</target_duration>
  <primary_outcome>
    <measure>Sensitivity and Specificity</measure>
    <time_frame>7 years</time_frame>
    <description>Evaluate ctDNA's ability to detect disease recurrence as compared to standard of care techniques across solid tumors. With sensitivity being the proportion of participants with radiographic recurrence who first had a ctDNA recurrence and specificity being the proportion of participants without radiographic recurrence who did not first have a ctDNA recurrence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ctDNA Clearance</measure>
    <time_frame>7 years</time_frame>
    <description>Compare the clinical benefit of biomarker guided adjuvant therapy versus standard adjuvant therapy in ctDNA-positive participants. With ctDNA clearance being the proportion of ctDNA-positive patients that are ctDNA negative ~6 months post-treatment initiation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS) - biomarker guided adjuvant therapy versus standard adjuvant therapy in ctDNA-positive participants</measure>
    <time_frame>7 years</time_frame>
    <description>Compare the clinical benefit of biomarker guided adjuvant therapy versus standard adjuvant therapy in ctDNA-positive participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS) - standard adjuvant therapy to no-adjuvant therapy in ctDNA-negative patients</measure>
    <time_frame>7 years</time_frame>
    <description>Compare the clinical benefit of standard adjuvant therapy to no-adjuvant therapy in ctDNA-negative patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS) - standard adjuvant therapy to no-adjuvant therapy in ctDNA-positive patients</measure>
    <time_frame>7 years</time_frame>
    <description>Compare the clinical benefit of standard adjuvant therapy to no-adjuvant therapy in ctDNA-positive patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and Specificity</measure>
    <time_frame>7 years</time_frame>
    <description>Determine tumor types where ctDNA-based MRD informed by NGS outperforms traditional biomarker/imaging-based recurrence monitoring</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Examine changes in ctDNA levels over time as a surrogate marker for disease free survival (DFS)</measure>
    <time_frame>7 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Examine the correlation between baseline tissue-derived biomarkers by StrataMRD testing and changes to ctDNA levels over time</measure>
    <time_frame>7 years</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. FFPE tumor tissue sample (study initiation collection)&#xD;
&#xD;
        2. 20mL blood sample (collection every 3 months)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants are male or female ≥ 18 years of age; with a confirmed diagnosis of a stage&#xD;
        1-3 solid tumor; or have curative surgery or definitive therapy (e.g., chemoradiation,&#xD;
        SBRT) planned within 28 days of consent or occurred without any current evidence of&#xD;
        radiographical or biochemical recurrence; are able to tolerate venipuncture for blood&#xD;
        draws; and their primary diagnosis is not glioma or CNS disease. Both the tumor tissue&#xD;
        sample and blood sample pass the quantity and quality parameters to allow for successful&#xD;
        MRD test result&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants ≥ 18 years of age;&#xD;
&#xD;
          -  Confirmed diagnosis of a stage 1-3 solid tumor; or&#xD;
&#xD;
          -  Curative surgery or definitive therapy (e.g., chemoradiation, SBRT) planned within 28&#xD;
             days of consent or occurred without any current evidence of radiographical or&#xD;
             biochemical recurrence;&#xD;
&#xD;
          -  Able to tolerate venipuncture for blood draws; and&#xD;
&#xD;
          -  Primary diagnosis is not glioma or CNS disease.&#xD;
&#xD;
          -  Both the tumor tissue sample and blood sample pass the quantity and quality parameters&#xD;
             to allow for a successful MRD test result&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kat Kwiatkowski, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Strata Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Bush</last_name>
    <phone>(734) 527-1000</phone>
    <email>stephanie.bush@strataoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephannie Perrin</last_name>
    <phone>(734) 527-1000</phone>
    <email>stephannie.perrin@strataoncology.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.</citation>
    <PMID>33538338</PMID>
  </reference>
  <reference>
    <citation>Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019 Sep;69(5):363-385. doi: 10.3322/caac.21565. Epub 2019 Jun 11.</citation>
    <PMID>31184787</PMID>
  </reference>
  <reference>
    <citation>Böckelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol. 2015 Jan;54(1):5-16. doi: 10.3109/0284186X.2014.975839. Epub 2014 Nov 28. Review.</citation>
    <PMID>25430983</PMID>
  </reference>
  <reference>
    <citation>Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, Heilskov Rasmussen M, Vang S, Shchegrova S, Frydendahl Boll Johansen A, Srinivasan R, Assaf Z, Balcioglu M, Olson A, Dashner S, Hafez D, Navarro S, Goel S, Rabinowitz M, Billings P, Sigurjonsson S, Dyrskjøt L, Swenerton R, Aleshin A, Laurberg S, Husted Madsen A, Kannerup AS, Stribolt K, Palmelund Krag S, Iversen LH, Gotschalck Sunesen K, Lin CJ, Zimmermann BG, Lindbjerg Andersen C. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019 Aug 1;5(8):1124-1131. doi: 10.1001/jamaoncol.2019.0528. Erratum in: JAMA Oncol. 2019 Jun 13;:.</citation>
    <PMID>31070691</PMID>
  </reference>
  <reference>
    <citation>Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, Ali S, Cleator S, Kenny L, Stebbing J, Rutherford M, Sethi H, Boydell A, Swenerton R, Fernandez-Garcia D, Gleason KLT, Goddard K, Guttery DS, Assaf ZJ, Wu HT, Natarajan P, Moore DA, Primrose L, Dashner S, Tin AS, Balcioglu M, Srinivasan R, Shchegrova SV, Olson A, Hafez D, Billings P, Aleshin A, Rehman F, Toghill BJ, Hills A, Louie MC, Lin CJ, Zimmermann BG, Shaw JA. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin Cancer Res. 2019 Jul 15;25(14):4255-4263. doi: 10.1158/1078-0432.CCR-18-3663. Epub 2019 Apr 16.</citation>
    <PMID>30992300</PMID>
  </reference>
  <reference>
    <citation>Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.</citation>
    <PMID>32955177</PMID>
  </reference>
  <reference>
    <citation>Vidal J, Casadevall D, Bellosillo B, Pericay C, Garcia-Carbonero R, Losa F, Layos L, Alonso V, Capdevila J, Gallego J, Vera R, Salud A, Martin-Richard M, Nogué M, Cillán E, Maurel J, Faull I, Raymond V, Fernández-Martos C, Montagut C. Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial. Clin Cancer Res. 2021 May 15;27(10):2890-2898. doi: 10.1158/1078-0432.CCR-20-4769. Epub 2021 Mar 16.</citation>
    <PMID>33727257</PMID>
  </reference>
  <reference>
    <citation>Powels, T.B. et al., Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy. Annals of Oncology, 2020. 31(suppl_7): S1417-S1424.</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

